114 related articles for article (PubMed ID: 15459489)
1. Protein kinase C alpha expression in breast and ovarian cancer.
Lahn M; Köhler G; Sundell K; Su C; Li S; Paterson BM; Bumol TF
Oncology; 2004; 67(1):1-10. PubMed ID: 15459489
[TBL] [Abstract][Full Text] [Related]
2. The role of protein kinase C-alpha in malignancies of the nervous system and implications for the clinical development of the specific PKC-alpha inhibitor aprinocarsen (Review).
Lahn MM; Sundell KL; Paterson BM
Oncol Rep; 2004 Feb; 11(2):515-22. PubMed ID: 14719093
[TBL] [Abstract][Full Text] [Related]
3. The role of protein kinase C-alpha in hematologic malignancies.
Lahn M; Sundell K; Köhler G
Acta Haematol; 2006; 115(1-2):1-8. PubMed ID: 16424642
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
Roychowdhury D; Lahn M
Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer.
Fournier DB; Chisamore M; Lurain JR; Rademaker AW; Jordan VC; Tonetti DA
Gynecol Oncol; 2001 Jun; 81(3):366-72. PubMed ID: 11371124
[TBL] [Abstract][Full Text] [Related]
7. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
Advani R; Peethambaram P; Lum BL; Fisher GA; Hartmann L; Long HJ; Halsey J; Holmlund JT; Dorr A; Sikic BI
Cancer; 2004 Jan; 100(2):321-6. PubMed ID: 14716767
[TBL] [Abstract][Full Text] [Related]
8. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.
Zhang L; Huang J; Yang N; Liang S; Barchetti A; Giannakakis A; Cadungog MG; O'Brien-Jenkins A; Massobrio M; Roby KF; Katsaros D; Gimotty P; Butzow R; Weber BL; Coukos G
Cancer Res; 2006 May; 66(9):4627-35. PubMed ID: 16651413
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?
Ratnasinghe D; Daschner PJ; Anver MR; Kasprzak BH; Taylor PR; Yeh GC; Tangrea JA
Anticancer Res; 2001; 21(3C):2141-7. PubMed ID: 11501838
[TBL] [Abstract][Full Text] [Related]
10. Hormonal regulation of PKC: estrogen up-regulates PKCeta expression in estrogen-responsive breast cancer cells.
Karp G; Maissel A; Livneh E
Cancer Lett; 2007 Feb; 246(1-2):173-81. PubMed ID: 16580129
[TBL] [Abstract][Full Text] [Related]
11. Induction of a less aggressive breast cancer phenotype by protein kinase C-alpha and -beta overexpression.
Manni A; Buckwalter E; Etindi R; Kunselman S; Rossini A; Mauger D; Dabbs D; Demers L
Cell Growth Differ; 1996 Sep; 7(9):1187-98. PubMed ID: 8877100
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides targeting protein kinase C-alpha, -beta I, or -delta but not -eta inhibit lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages: involvement of a nuclear factor kappa B-dependent mechanism.
Chen CC; Wang JK; Lin SB
J Immunol; 1998 Dec; 161(11):6206-14. PubMed ID: 9834107
[TBL] [Abstract][Full Text] [Related]
13. Disparity in expression of protein kinase C alpha in human glioma versus glioma-derived primary cell lines: therapeutic implications.
Zellner A; Fetell MR; Bruce JN; De Vivo DC; O'Driscoll KR
Clin Cancer Res; 1998 Jul; 4(7):1797-802. PubMed ID: 9676858
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo assays to evaluate the role of protein kinase C in tumor cells of patients with breast cancer.
Schöndorf T; Becker M; Kolhagen H; Kurbacher CM; Göhring UJ
Anticancer Res; 2000; 20(6D):5073-6. PubMed ID: 11326671
[TBL] [Abstract][Full Text] [Related]
15. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
16. Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes.
Lee YS; Dlugosz AA; McKay R; Dean NM; Yuspa SH
Mol Carcinog; 1997 Jan; 18(1):44-53. PubMed ID: 9022812
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Walker G; MacLeod K; Williams AR; Cameron DA; Smyth JF; Langdon SP
Gynecol Oncol; 2007 Sep; 106(3):461-8. PubMed ID: 17624412
[TBL] [Abstract][Full Text] [Related]
18. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
19. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.
Nabha SM; Glaros S; Hong M; Lykkesfeldt AE; Schiff R; Osborne K; Reddy KB
Oncogene; 2005 Apr; 24(19):3166-76. PubMed ID: 15735693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
